6533b82ffe1ef96bd129501c
RESEARCH PRODUCT
Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
Ajay K. NookaHimal AminAsher Chanan-khanTahamtan AhmadiPieter SonneveldMarkus MunderMeral BeksacWilliam DeraedtIvan SpickaAndrew SpencerAntonio PalumboTamás MassziJordan M. SchecterXiang QinMing QiV. HungriaTomer M MarkM.v. MateosKatja Weiselsubject
Oncologymedicine.medical_specialtyBortezomibbusiness.industryDaratumumabRefractory Multiple MyelomaHematology030218 nuclear medicine & medical imagingSurgery03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicineIn patientbusinessDexamethasonemedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2016-10-01 | Annals of Oncology |